Supply issues to continue in 2023, reports Novo Nordisk

Investing massively into increasing production capacity, Novo Nordisk hopes to increase its drug supply, though 2023 will still see ”periodic supply constraints,” informs Novo CFO Karsten Munk Knudsen.
Photo: Fabian Bimmer/Reuters/Ritzau Scanpix
Photo: Fabian Bimmer/Reuters/Ritzau Scanpix
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Overcoming challenges of matching capacity to full demand for some products has been an overall theme for Danish drugmaker Novo Nordisk’s 2022.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading